• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.

作者信息

Nitro Letizia, Bulfamante Antonio Mario, Rosso Cecilia, Saibene Alberto Maria, Arnone Flavio, Felisati Giovanni, Pipolo Carlotta

机构信息

Otolaryngology Unit, Santi Paolo e Carlo Hospital, Department of Health Sciences, Università degli Studi di Milano, Milan, Italy.

出版信息

Acta Otorhinolaryngol Ital. 2022 Jun;42(3):199-204. doi: 10.14639/0392-100X-N1911.

DOI:10.14639/0392-100X-N1911
PMID:35880360
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9330752/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/9330752/334c2eec311d/aoi-2022-03-199-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/9330752/334c2eec311d/aoi-2022-03-199-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7045/9330752/334c2eec311d/aoi-2022-03-199-g002.jpg

相似文献

1
Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review.度普利尤单抗治疗伴有鼻息肉的慢性鼻-鼻窦炎的不良反应。病例报告及叙述性综述
Acta Otorhinolaryngol Ital. 2022 Jun;42(3):199-204. doi: 10.14639/0392-100X-N1911.
2
Efficacy of dupilumab on chronic rhinosinusitis with nasal polyps and concomitant asthma in biologic-naive and biologic-pretreated patients.度普利尤单抗治疗生物制剂初治和生物制剂预处理的慢性鼻-鼻窦炎伴鼻息肉和哮喘患者的疗效。
Ann Med. 2024 Dec;56(1):2411018. doi: 10.1080/07853890.2024.2411018. Epub 2024 Oct 4.
3
Efficacy and Safety of Dupilumab Versus Omalizumab in Chronic Rhinosinusitis With Nasal Polyps and Asthma: EVEREST Trial Design.度普利尤单抗对比奥马珠单抗治疗伴有鼻息肉的慢性鼻-鼻窦炎和哮喘的疗效和安全性：EVEREST 试验设计。
Am J Rhinol Allergy. 2022 Nov;36(6):788-795. doi: 10.1177/19458924221112211. Epub 2022 Jul 15.
4
Dupilumab for the treatment of chronic rhinosinusitis with nasal polyposis.度普利尤单抗治疗伴有鼻息肉的慢性鼻-鼻窦炎。
Expert Opin Biol Ther. 2021 May;21(5):575-585. doi: 10.1080/14712598.2021.1901881. Epub 2021 Apr 1.
5
Dupilumab in pediatric severe chronic rhinosinusitis with nasal polyps and asthma.度普利尤单抗治疗小儿重度慢性鼻-鼻窦炎伴鼻息肉和哮喘
Eur Ann Otorhinolaryngol Head Neck Dis. 2024 Jan;141(1):55-56. doi: 10.1016/j.anorl.2023.06.006. Epub 2023 Aug 15.
6
Cost Utility Analysis of Dupilumab Versus Endoscopic Sinus Surgery for Chronic Rhinosinusitis With Nasal Polyps.度普利尤单抗与内镜鼻窦手术治疗鼻息肉慢性鼻-鼻窦炎的成本效用分析。
Laryngoscope. 2021 Jan;131(1):E26-E33. doi: 10.1002/lary.28648. Epub 2020 Apr 3.
7
Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS-24 and SINUS-52.两项 3 期临床试验（SINUS-24 和 SINUS-52）中，慢性鼻-鼻窦炎伴鼻息肉患者的 2 型炎症特征的流行情况和度普利尤单抗的疗效。
Int Forum Allergy Rhinol. 2024 Mar;14(3):668-678. doi: 10.1002/alr.23249. Epub 2023 Aug 22.
8
Comorbid asthma in patients with chronic rhinosinusitis with nasal polyps: did dupilumab make a difference?慢性鼻-鼻窦炎伴鼻息肉患者的合并哮喘：度普利尤单抗是否有影响？
BMC Pulm Med. 2023 Jul 18;23(1):266. doi: 10.1186/s12890-023-02556-8.
9
Effectiveness of dupilumab versus endoscopic sinus surgery for the treatment of type-2 chronic rhinosinusitis with nasal polyps: a preliminary report.度普利尤单抗与鼻内镜手术治疗2型慢性鼻-鼻窦炎伴鼻息肉的疗效比较：初步报告
Eur Arch Otorhinolaryngol. 2024 Mar;281(3):1317-1324. doi: 10.1007/s00405-023-08309-x. Epub 2023 Nov 1.
10
Real-World Adverse Events After Type 2 Biologic use in Chronic Rhinosinusitis with Nasal Polyps.2 型生物制剂治疗慢性鼻-鼻窦炎伴鼻息肉的真实世界不良事件。
Laryngoscope. 2024 Jul;134(7):3054-3059. doi: 10.1002/lary.31305. Epub 2024 Feb 5.

引用本文的文献

1
Remission in chronic rhinosinusitis with nasal polyps treated with biologics: a real-life experience.生物制剂治疗鼻息肉型慢性鼻-鼻窦炎的缓解情况：真实病例经验
Eur Arch Otorhinolaryngol. 2025 Sep;282(9):4681-4690. doi: 10.1007/s00405-025-09619-y. Epub 2025 Aug 4.
2
Role of body mass index as a predictor of dupilumab efficacy in patients with severe chronic rhinosinusitis with nasal polyps.体重指数作为重度慢性鼻-鼻窦炎伴鼻息肉患者度普利尤单抗疗效预测指标的作用
Acta Otorhinolaryngol Ital. 2025 Feb;45(1):28-38. doi: 10.14639/0392-100X-N2841.
3
Comparison between clinical and cytological findings in chronic rhinosinusitis with nasal polyps treated with Dupilumab.

本文引用的文献

1
Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID-ERD: Results from two randomized placebo-controlled phase 3 trials.度普利尤单抗治疗未得到控制的伴有鼻息肉的重度慢性鼻-鼻窦炎和 NSAID-ERD 临床诊断患者的疗效和安全性：两项随机安慰剂对照 3 期临床试验的结果。
Allergy. 2022 Apr;77(4):1231-1244. doi: 10.1111/all.15067. Epub 2021 Oct 1.
2
Dupilumab reduces systemic corticosteroid use and sinonasal surgery rate in CRSwNP.度普利尤单抗可降低 CRSwNP 患者全身皮质类固醇使用率和鼻内镜鼻窦手术率。
Rhinology. 2021 Jun 1;59(3):301-311. doi: 10.4193/Rhin20.415.
3
比较度普利尤单抗治疗慢性鼻-鼻窦炎伴鼻息肉的临床和细胞学发现。
Eur Arch Otorhinolaryngol. 2024 Dec;281(12):6511-6521. doi: 10.1007/s00405-024-08958-6. Epub 2024 Sep 16.
4
Switching of biological therapy to dupilumab in comorbid patients with severe asthma and CRSwNP.将生物疗法转换为度普利尤单抗治疗合并严重哮喘和 CRSwNP 的患者。
Eur Arch Otorhinolaryngol. 2024 Jun;281(6):3017-3023. doi: 10.1007/s00405-024-08461-y. Epub 2024 Feb 12.
5
Dupilumab's Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life.度普利尤单抗对鼻息肉患者血液参数的影响：真实世界 18 个月随访。
J Immunol Res. 2023 Sep 15;2023:4027701. doi: 10.1155/2023/4027701. eCollection 2023.
6
Effectiveness and Safety Profile of Dupilumab in Chronic Rhinosinusitis with Nasal Polyps: Real-Life Data in Tertiary Care.度普利尤单抗治疗伴鼻息肉的慢性鼻-鼻窦炎的有效性和安全性概况：三级医疗中心的真实世界数据
Pharmaceuticals (Basel). 2023 Apr 21;16(4):630. doi: 10.3390/ph16040630.
Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps.
伴有鼻息肉的慢性鼻-鼻窦炎的疾病负担
J Asthma Allergy. 2021 Feb 11;14:127-134. doi: 10.2147/JAA.S290424. eCollection 2021.
4
Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.真实世界中评估度普利尤单抗疗效和不良事件风险的证据：一项系统评价和荟萃分析。
J Am Acad Dermatol. 2021 Jan;84(1):139-147. doi: 10.1016/j.jaad.2020.08.051. Epub 2020 Aug 18.
5
Prognostic value of the Sinonasal Outcome Test 22 (SNOT-22) in chronic rhinosinusitis.鼻窦结局测试22（SNOT-22）在慢性鼻-鼻窦炎中的预后价值。
Acta Otorhinolaryngol Ital. 2020 Apr;40(2):113-121. doi: 10.14639/0392-100X-N0364.
6
Therapeutic Potential of Dupilumab in the Treatment of Chronic Rhinosinusitis with Nasal Polyps: Evidence to Date.度普利尤单抗治疗伴鼻息肉的慢性鼻-鼻窦炎的治疗潜力：迄今的证据
Ther Clin Risk Manag. 2020 Jan 23;16:31-37. doi: 10.2147/TCRM.S210648. eCollection 2020.
7
Biologics for chronic rhinosinusitis with nasal polyps.生物制剂治疗慢性鼻-鼻窦炎伴鼻息肉
J Allergy Clin Immunol. 2020 Mar;145(3):725-739. doi: 10.1016/j.jaci.2020.01.020.
8
Biologics for chronic rhinosinusitis.用于慢性鼻-鼻窦炎的生物制剂。
Cochrane Database Syst Rev. 2020 Feb 27;2(2):CD013513. doi: 10.1002/14651858.CD013513.pub2.
9
Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.生物制剂（贝那利珠单抗、度普利尤单抗、美泊利单抗、奥马珠单抗和瑞利珠单抗）治疗重度嗜酸性粒细胞性哮喘的疗效和安全性。EAACI指南的系统评价——关于生物制剂在重度哮喘中应用的建议
Allergy. 2020 May;75(5):1023-1042. doi: 10.1111/all.14221. Epub 2020 Feb 24.
10
The role of biologics in chronic rhinosinusitis: a systematic review.生物制剂在慢性鼻-鼻窦炎中的作用：系统评价。
Int Forum Allergy Rhinol. 2020 Feb;10(2):165-174. doi: 10.1002/alr.22473. Epub 2019 Dec 23.